In vivo blockade of TLR5 with soluble decoy receptors (sTLR5Fc) significantly lowered the amyloid plaque burden and Aβ42 levels in TgCRND8 mouse model of AD. The gene discussed is TLR5; the disease is Alzheimer disease.